Cargando…

Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer

PURPOSE: Specific gene fusions and their fusion products (chimeric RNA and protein) have served as ideal diagnostic markers and therapeutic targets for cancer. However, few systematic studies for chimeric RNAs have been conducted in neuroendocrine prostate cancer (NEPC). In this study, we explored t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiong, Chen, Junxiu, Singh, Sandeep, Xie, Zhongqiu, Qin, Fujun, Shi, Xinrui, Cornelison, Robert, Li, Hui, Huang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463804/
https://www.ncbi.nlm.nih.gov/pubmed/36088396
http://dx.doi.org/10.1186/s13578-022-00893-5
_version_ 1784787465952821248
author Wang, Qiong
Chen, Junxiu
Singh, Sandeep
Xie, Zhongqiu
Qin, Fujun
Shi, Xinrui
Cornelison, Robert
Li, Hui
Huang, Hai
author_facet Wang, Qiong
Chen, Junxiu
Singh, Sandeep
Xie, Zhongqiu
Qin, Fujun
Shi, Xinrui
Cornelison, Robert
Li, Hui
Huang, Hai
author_sort Wang, Qiong
collection PubMed
description PURPOSE: Specific gene fusions and their fusion products (chimeric RNA and protein) have served as ideal diagnostic markers and therapeutic targets for cancer. However, few systematic studies for chimeric RNAs have been conducted in neuroendocrine prostate cancer (NEPC). In this study, we explored the landscape of chimeric RNAs in different types of prostate cancer (PCa) cell lines and aimed to identify chimeric RNAs specifically expressed in NEPC. METHODS: To do so, we employed the RNA-seq data of eight prostate related cell lines from Cancer Cell Line Encyclopedia (CCLE) for chimeric RNA identification. Multiple filtering criteria were used and the candidate chimeric RNAs were characterized at multiple levels and from various angles. We then performed experimental validation on all 80 candidates, and focused on the ones that are specific to NEPC. Lastly, we studied the clinical relevance and effect of one chimera in neuroendocrine process. RESULTS: Out of 80 candidates, 15 were confirmed to be expressed preferentially in NEPC lines. Among them, 13 of the 15 were found to be specifically expressed in NEPC, and four were further validated in another NEPC cell line. Importantly, in silico analysis showed that tumor malignancy may be correlated to the level of these chimeric RNAs. Clinically, the expression of TMPRSS2-ERG (e2e4) was elevated in tumor tissues and indicated poor clinical prognosis, whereas the parental wild type transcripts had no such association. Furthermore, compared to the most frequently detected TMPRSS2-ERG form (e1e4), e2e4 encodes 31 more amino acids and accelerated neuroendocrine process of prostate cancer. CONCLUSIONS: In summary, these findings painted the landscape of chimeric RNA in NEPC and supported the idea that some chimeric RNAs may represent additional biomarkers and/or treatment targets independent of parental gene transcripts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00893-5.
format Online
Article
Text
id pubmed-9463804
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94638042022-09-11 Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer Wang, Qiong Chen, Junxiu Singh, Sandeep Xie, Zhongqiu Qin, Fujun Shi, Xinrui Cornelison, Robert Li, Hui Huang, Hai Cell Biosci Research PURPOSE: Specific gene fusions and their fusion products (chimeric RNA and protein) have served as ideal diagnostic markers and therapeutic targets for cancer. However, few systematic studies for chimeric RNAs have been conducted in neuroendocrine prostate cancer (NEPC). In this study, we explored the landscape of chimeric RNAs in different types of prostate cancer (PCa) cell lines and aimed to identify chimeric RNAs specifically expressed in NEPC. METHODS: To do so, we employed the RNA-seq data of eight prostate related cell lines from Cancer Cell Line Encyclopedia (CCLE) for chimeric RNA identification. Multiple filtering criteria were used and the candidate chimeric RNAs were characterized at multiple levels and from various angles. We then performed experimental validation on all 80 candidates, and focused on the ones that are specific to NEPC. Lastly, we studied the clinical relevance and effect of one chimera in neuroendocrine process. RESULTS: Out of 80 candidates, 15 were confirmed to be expressed preferentially in NEPC lines. Among them, 13 of the 15 were found to be specifically expressed in NEPC, and four were further validated in another NEPC cell line. Importantly, in silico analysis showed that tumor malignancy may be correlated to the level of these chimeric RNAs. Clinically, the expression of TMPRSS2-ERG (e2e4) was elevated in tumor tissues and indicated poor clinical prognosis, whereas the parental wild type transcripts had no such association. Furthermore, compared to the most frequently detected TMPRSS2-ERG form (e1e4), e2e4 encodes 31 more amino acids and accelerated neuroendocrine process of prostate cancer. CONCLUSIONS: In summary, these findings painted the landscape of chimeric RNA in NEPC and supported the idea that some chimeric RNAs may represent additional biomarkers and/or treatment targets independent of parental gene transcripts. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00893-5. BioMed Central 2022-09-10 /pmc/articles/PMC9463804/ /pubmed/36088396 http://dx.doi.org/10.1186/s13578-022-00893-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Qiong
Chen, Junxiu
Singh, Sandeep
Xie, Zhongqiu
Qin, Fujun
Shi, Xinrui
Cornelison, Robert
Li, Hui
Huang, Hai
Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
title Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
title_full Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
title_fullStr Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
title_full_unstemmed Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
title_short Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer
title_sort profile of chimeric rnas and tmprss2-erg e2e4 isoform in neuroendocrine prostate cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463804/
https://www.ncbi.nlm.nih.gov/pubmed/36088396
http://dx.doi.org/10.1186/s13578-022-00893-5
work_keys_str_mv AT wangqiong profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT chenjunxiu profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT singhsandeep profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT xiezhongqiu profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT qinfujun profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT shixinrui profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT cornelisonrobert profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT lihui profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer
AT huanghai profileofchimericrnasandtmprss2erge2e4isoforminneuroendocrineprostatecancer